CX3CL1 and pancreatic adenocarcinoma: CX3CL1 expression was dramatically increased in older patients (≥65 years) with liver hepatocellular carcinoma (LIHC), while dramatically decreased in older patients with brain lower grade glioma (LGG), BRCA, PAAD, and STAD (Figure 2A).